Alumis Completes Merger with ACELYRIN
Provided By GlobeNewswire
Last update: May 21, 2025
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc.
Read more at globenewswire.com6.92
+0.35 (+5.33%)
Find more stocks in the Stock Screener
ALMS Latest News and Analysis
